Esperion Therapeutics, Inc. (ESPR)

1.4900 -0.0900 (-5.70%) At close: 04:00PM EST

Esperion Therapeutics, Inc.

3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734 887 3903
https://www.esperion.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 199

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Sheldon L. Koenig	President, CEO & Director	1.2M	N/A	1966
Mr. Benjamin O. Looker	General Counsel	550.35k	N/A	1982
Dr. JoAnne Micale Foody FACC, M.D.	Chief Medical Officer	771.19k	N/A	1966
Mr. Benjamin Halladay M.B.A.	Chief Financial Officer	N/A	N/A	1986
Mr. Glenn P. Brame	Chief Technical Operations Officer	N/A	N/A	1958
Tiffany Aldrich M.B.A.	Associate Director of Corporate Communications	N/A	N/A	N/A
Ms. Betty Jean Swartz	Chief Business Officer	N/A	N/A	N/A
Mr. Eric J. Warren R.Ph.	Chief Commercial Officer	N/A	N/A	1972

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Corporate governance

Esperion Therapeutics, Inc.’s ISS governance QualityScore as of 1 December 2023 is 7. The pillar scores are Audit: 4; Board: 5; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.